title: Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
abstract: OBJECTIVE
  This study aimed to assess the clinical efficacy and toxicity of sunitinib, a targeted-agent, for non-clear cell renal cell carcinoma.
  
  
  METHODS
  Sixty-three patients with complete clinical data from 13 oncology Centers were retrospectively evaluated. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events.
  
  
  RESULTS
  The median age of all patients, 38 men (60.3%) and 25 women (39.7%), was 63 years (range=25-82 years). Histological subtypes included 46 (88%) cases of papillary RCC, 10 of chromophobe, and 7 unclassified cases. Median treatment duration was seven months (range=2-86 months). At the time of this analysis, 52 patients had discontinued treatment, 33 of whom had died. Treatment discontinuation was due to disease progression in 43 patients, and toxicity in nine. Dose interruption was necessary in 22 (34.9%) patients, and dose reduction in 27 (42.9%). The objective response rate and disease control rate were 11.1% and 63.5%, respectively. The median PFS and OS were 7.6 months (95% confidence interval (CI)=5.5-9.7 months) and 22.0 months (95% CI=13.4-30.6 months), respectively, with 1-year rates of 64.7% and 33.7%, respectively.
  
  
  CONCLUSIONS
  Clinical outcome of the metastatic non-clear cell RCC patients with sunitinib treatment seemed to be worse than the historical data of clear cell RCC patients, in terms of PFS, OS and objective response. New and more effective targeted-therapies and better understanding of the underlying molecular processes are necessary to improve survival outcome for these patients.
authors: Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey dr_ibrahim2000@yahoo.com.
authors: Ibrahim
authors: I
authors: Yildiz
authors: Departments of Medical Oncology at: Institute of Oncology, Istanbul University, Istanbul, Turkey.
authors: Meltem
authors: M
authors: Ekenel
authors: Departments of Medical Oncology at: Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
authors: Tulay
authors: T
authors: Akman
authors: Departments of Medical Oncology at: Sanliurfa Education and Research Hospital, Sanliurfa, Turkey.
authors: Muharrem
authors: M
authors: Kocar
authors: Departments of Medical Oncology at: Afyon Kocatepe University, Afyonkarahisar, Turkey.
authors: Mükremin
authors: M
authors: Uysal
authors: Departments of Medical Oncology at: Marmara University Hospital, Istanbul, Turkey.
authors: Metin
authors: M
authors: Kanitez
authors: Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey.
authors: Umut
authors: U
authors: Varol
authors: Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey.
authors: Ibrahim Vedat
authors: IV
authors: Bayoglu
authors: Departments of Medical Oncology at: Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
authors: Deniz
authors: D
authors: Tural
authors: Departments of Medical Oncology at: Dicle University, Diyarbakir, Turkey.
authors: Mehmet Ali
authors: MA
authors: Kaplan
authors: Departments of Medical Oncology at: Balikesir State Hospital, Balikesir, Turkey.
authors: Nilufer
authors: N
authors: Avci
authors: Departments of Medical Oncology at: Ege University, Tulay Aktas Oncology Hospital, Izmir, Turkey.
authors: Zeki
authors: Z
authors: Sürmeli
authors: Departments of Medical Oncology at: Ankara University Medical Faculty, Ankara, Turkey.
authors: İsa
authors: İ
authors: Dede
authors: Departments of Medical Oncology at: Ali Osman Sonmez Oncology Training and Research Hospital, Bursa, Turkey.
authors: Arife
authors: A
authors: Ulaş
authors: Departments of Medical Oncology at: Ankara Numune Education and Research Hospital, Ankara, Turkey.
authors: Ozan
authors: O
authors: Yazici
authors: Departments of Medical Oncology at: Institute of Oncology, Istanbul University, Istanbul, Turkey.
authors: Mert
authors: M
authors: Basaran
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
keywords: Adverse effects; metastatic non-clear cell renal cell carcinoma; sunitinib